Tumor Markers in Lung Cancer: DCAMLK-1LK-1

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gary Kinasewitz, University of Oklahoma
ClinicalTrials.gov Identifier:
NCT01578018
First received: April 11, 2012
Last updated: August 8, 2012
Last verified: August 2012

April 11, 2012
August 8, 2012
December 2011
July 2012   (final data collection date for primary outcome measure)
Tumor Markers in Lung Cancer: [ Time Frame: 6 months ] [ Designated as safety issue: No ]
DCAMLK-1LK-1 levels will be measured in the blood of patients with Lung Cancer and compared to that of controls with other lung diseases.
Same as current
Complete list of historical versions of study NCT01578018 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Tumor Markers in Lung Cancer: DCAMLK-1LK-1
Tumor Markers in Lung Cancer: DCAMLK-1LK-1: A Pilot Study

DCAMLK1 is a Ca2+ - ca/modulin (CaM) - dependent protein kinase that is a marker of stem cells in colonic crypts. Mutations within the stem cell population are thought to be responsible for the development of most colorectal carcinomas and studies have shown that DCAMLK1 is highly expressed in these tumors. Since the lung is an embryological development of the foregut, the investigators speculate that DCAMLK1 will also be upregulated in lung cancers.

The aim of this pilot study is to measure DCAMLK1 levels in the blood of patients with suspected malignant and benign lung diseases, and to correlate DCAMKL1 levels with smoking status.

In the investigators' preliminary study DCAMKL1 antigen was detected not only in malignant tissue, but also in BAL fluid from patients with benign lung disease. This suggests that DCAMKL1 expression might be induced by smoking or benign lung diseases. To examine this hypothesis, the investigators will compare DCAMLK1 expression in blood from patients with lung cancer to controls who are current or former smokers with benign lung disease.

Previous work has showed that DCAMLK1 is not detectable in the blood of healthy non smoking individuals. To determine whether smoking and or pulmonary inflammation induce DCAMLK1 expression, the investigators will obtain serum samples from 20 control patients with lung disease who are seen in the Chest Clinic at the Oklahoma City VAMC. Smoking histories will be obtained for all participants and DCAMLK1 levels will be correlated with smoking status.

Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Lung Cancer
  • Smoking
  • Other: Measure DCAM levels in blood
    Measure DCAM levels in blood
    Other Name: Lung Cancer
  • Other: DCAM levels in blood
    DCAM levels in blood
    Other Name: Lung Disease
  • Lung Cancer
    Diagnostic
    Intervention: Other: Measure DCAM levels in blood
  • Lung Disease
    Diagnostic
    Intervention: Other: DCAM levels in blood
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
49
July 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • >45 years of age

Exclusion Criteria:

  • Unable to provide informed consent
Both
45 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01578018
16249
No
Gary Kinasewitz, University of Oklahoma
University of Oklahoma
Not Provided
Principal Investigator: Kellie Jones, MD University of Oklahoma
University of Oklahoma
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP